B
16.19
-1.60 (-8.99%)
| Previous Close | 17.79 |
| Open | 17.68 |
| Volume | 269,532 |
| Avg. Volume (3M) | 684,038 |
| Market Cap | 718,508,224 |
| Price / Sales | 73.30 |
| Price / Book | 2.99 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2026 |
| Operating Margin (TTM) | -1,133.43% |
| Diluted EPS (TTM) | -1.98 |
| Total Debt/Equity (MRQ) | 3.29% |
| Current Ratio (MRQ) | 13.68 |
| Operating Cash Flow (TTM) | -53.21 M |
| Levered Free Cash Flow (TTM) | -34.85 M |
| Return on Assets (TTM) | -19.54% |
| Return on Equity (TTM) | -30.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | BioAge Labs, Inc. | Bullish | Bullish |
AIStockmoo Score
1.0
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.00 |
|
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| % Held by Insiders | 3.63% |
| % Held by Institutions | 66.65% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Cosmic Management, Llc | 31 Dec 2025 | 501,833 |
| Redpoint Management, Llc | 31 Dec 2025 | 383,254 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 62.00 (Jefferies, 282.95%) | Buy |
| Median | 60.00 (270.60%) | |
| Low | 52.00 (Citigroup, 221.19%) | Buy |
| Average | 58.00 (258.25%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 20.90 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 10 Mar 2026 | 52.00 (221.19%) | Buy | 20.97 |
| Oppenheimer | 25 Feb 2026 | 60.00 (270.60%) | Buy | 22.14 |
| Jefferies | 18 Feb 2026 | 62.00 (282.95%) | Buy | 19.59 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GOLDSTEIN DOV A MD | - | - | 0 | 0 |
| Aggregate Net Quantity | 0 | |||
| Aggregate Net Value ($) | 0 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| GOLDSTEIN DOV A MD | Officer | 23 Apr 2026 | Option execute | 3,542 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |